Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580931 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Nicotinamide to Treat Alzheimer's Disease
A Phase 1 study of Alzheimers Disease, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00580931 is a Phase 1 study of Alzheimers Disease that has completed, run by University of California, Irvine. The registered enrollment target is 50 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00580931, a Phase 1 study of Alzheimers Disease, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Nicotinamide
- DRUG Enduramide placebo
Study Locations (1)
California
- UC Irvine School of Medicine - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580931
The ClinicalTrials.gov registry entry for NCT00580931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Nicotinamide is the first listed.
NCT00580931 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00580931 about?
NCT00580931 is a clinical study titled "Safety Study of Nicotinamide to Treat Alzheimer's Disease". The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.
What is the current status of trial NCT00580931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2008-01. Estimated completion is 2014-07.
What conditions does trial NCT00580931 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00580931?
The interventions under investigation include: Nicotinamide (DRUG), Enduramide placebo (DRUG).
Who is sponsoring clinical trial NCT00580931?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00580931 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.